What are the indications, dosing regimen, contraindications, and monitoring recommendations for ticagrelor in adults with acute coronary syndrome or undergoing percutaneous coronary intervention?

Ticagrelor in Acute Coronary Syndrome

Ticagrelor (180 mg loading dose, then 90 mg twice daily) should be administered alongside low-dose aspirin (≤100 mg daily) in patients with acute coronary syndrome undergoing percutaneous coronary intervention to reduce major adverse cardiovascular events and stent thrombosis. 1

Indications

Ticagrelor is indicated for:

• NSTE-ACS (non-ST-elevation acute coronary syndrome)
• STEMI (ST-segment elevation myocardial infarction) managed without fibrinolytic therapy
• Patients undergoing percutaneous coronary intervention (PCI)

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines give ticagrelor a Class 1, Level B-R recommendation for STEMI patients managed with primary PCI, specifically stating it "should be administered to reduce MACE and stent thrombosis" 1. For all ACS patients, oral P2Y12 inhibitors (including ticagrelor) receive a Class 1, Level A recommendation to reduce major adverse cardiovascular events 1.

Dosing Regimen

Loading dose: 180 mg orally at presentation
Maintenance dose: 90 mg orally twice daily 1

Critical Aspirin Dosing Consideration

Always use aspirin ≤100 mg daily when combining with ticagrelor. Post hoc analysis from the PLATO trial demonstrated an association between higher aspirin doses and worse outcomes with ticagrelor 1. This is a unique requirement compared to other P2Y12 inhibitors.

Timing of Administration

For NSTE-ACS:

• If angiography anticipated >24 hours: Upstream treatment with ticagrelor may be considered (Class 2b, Level B-NR) 1
• If angiography anticipated ≤24 hours: Routine pretreatment is not suggested; can be given in the catheterization laboratory 2

For STEMI:

• Administer as soon as possible, preferably before or during primary PCI 1

Contraindications

Absolute Contraindications:

• History of stroke or transient ischemic attack - This is explicitly stated as a contraindication for prasugrel but not ticagrelor, making ticagrelor the preferred potent P2Y12 inhibitor in this population 1
• Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole) - contraindicated during and 2 weeks after treatment 3
• Active pathological bleeding
• History of intracranial hemorrhage

Relative Contraindications/Special Warnings:

• Asthma or chronic obstructive pulmonary disease - Ticagrelor can cause dyspnea (reversible upon discontinuation); this often favors clopidogrel selection in clinical practice 4
• Bradyarrhythmias - Ticagrelor may cause bradycardia, heart block, or sinus pauses
• Severe hepatic impairment
• Concomitant oral anticoagulation - Recent data shows increased bleeding risk when ticagrelor is combined with DOACs compared to clopidogrel, without additional ischemic benefit 5

Monitoring Recommendations

Bleeding Surveillance:

• Monitor for signs of bleeding (major and minor) throughout treatment
• BARC type 2,3, or 5 bleeding is the primary safety concern 6
• Recent evidence shows ticagrelor monotherapy (after 1 month of dual therapy) reduces bleeding by 55% compared to continued dual therapy (HR 0.45, p<0.0001) without increasing ischemic events 6

Respiratory Symptoms:

• Assess for dyspnea, particularly in first weeks of therapy
• Dyspnea occurs in approximately 10-15% of patients but is usually mild and self-limiting

Drug Interactions:

• Avoid strong CYP3A4 inhibitors and inducers
• Recent pharmacovigilance data identified significant signals for:
  • Rhabdomyolysis when combined with statins 7
  • Hemorrhagic complications with anticoagulants (especially heparin/enoxaparin) 7
  • Acute kidney injury with NSAIDs like ibuprofen 7
  • Urinary tract bleeding when combined with metoprolol 7

Renal Function:

• Monitor creatinine, particularly when combined with NSAIDs or other nephrotoxic agents

Duration of Therapy

Standard duration is 12 months after ACS/PCI 1. However, emerging evidence from the ULTIMATE-DAPT trial (2024) demonstrates that ticagrelor monotherapy starting at 1 month post-PCI (discontinuing aspirin) results in:

• 55% reduction in clinically relevant bleeding (2.1% vs 4.6%, p<0.0001)
• Non-inferior MACCE rates (3.6% vs 3.7%) 6

This suggests most event-free patients can transition to ticagrelor monotherapy after just 1 month of dual therapy, though current guidelines still recommend 12 months of dual therapy.

Comparative Considerations

Ticagrelor vs. Prasugrel: Recent meta-analysis shows equivalent efficacy and safety profiles 8. Choose based on:

• Ticagrelor preferred if: History of stroke/TIA, body weight <60 kg, age ≥75 years
• Prasugrel preferred if: Concerns about dyspnea, twice-daily dosing adherence issues, or need for once-daily regimen

Ticagrelor vs. Clopidogrel: Ticagrelor demonstrates superior reduction in MACE and mortality compared to clopidogrel in ACS patients 9. However, in patients requiring oral anticoagulation, clopidogrel may be safer due to lower bleeding risk 5.

Common Pitfalls

1. Using high-dose aspirin (>100 mg) with ticagrelor - Always use ≤100 mg daily
2. Continuing dual therapy beyond 1 month in low-risk patients - Consider early aspirin discontinuation
3. Prescribing to patients with prior stroke - Unlike prasugrel, this is not an absolute contraindication for ticagrelor
4. Ignoring dyspnea complaints - Reassure patients this is usually benign and reversible
5. Combining with strong CYP3A4 inhibitors - Absolutely contraindicated 3